Genetic Specificity of Mental Illness: A New Understanding

A recent study published in Genomic Psychiatry introduces the concept of genetic specificity, potentially reshaping how psychiatrists and geneticists approach mental illness. Led by Dr. Kenneth S. Kendler at Virginia Commonwealth University, the research analyzes data from over two million individuals to determine how much genetic vulnerability relates to a specific psychiatric disorder versus other diagnoses.

The Long-Standing Debate

The question of whether genetic transmission of mental illness is specific to individual disorders or represents a general predisposition has been debated since the 19th century. Twin studies, molecular analyses, and polygenic risk scores have all shown overlap in genetic risk factors across different psychiatric conditions. But, quantifying this phenomenon has remained a challenge.

Measuring Genetic Specificity

Dr. Kendler and his team, including researchers from Lund University in Sweden, developed a method to measure genetic specificity. They analyzed nine major psychiatric and substance use disorders: schizophrenia, bipolar disorder, alcohol use disorder, ADHD, autism spectrum disorder, PTSD, major depression, anxiety disorder, and drug use disorder. For each diagnosis, they calculated family genetic risk scores (FGRS) based on morbidity patterns among relatives. Genetic specificity was then determined by calculating the proportion of total genetic risk attributable specifically to the diagnosed disorder.

The study utilized a substantial dataset, including 674,955 individuals with depression and 18,348 with schizophrenia, encompassing over two million diagnostic records from Swedish national registers.

A Hierarchy of Genetic Specificity

The results revealed a striking hierarchy. Schizophrenia exhibited the highest genetic specificity at 73.1% (95% CI: 66.3 to 79.8), indicating that approximately three-quarters of the genetic risk in individuals with schizophrenia is specific to that disorder. Bipolar disorder followed at 54.8%, and alcohol use disorder at 54.1%.

ADHD (48.2%), autism spectrum disorder (47.5%), and PTSD (47.4%) formed a middle tier. Major depression registered 41.1%, anxiety disorder 38.6%, and drug use disorder a mere 29.5%. This suggests that less than a third of the genetic risk for individuals diagnosed with drug use disorder is specifically related to the condition itself.

“What surprised us was the sheer range,” said Dr. Kenneth S. Kendler, VIPBG Distinguished Professor of Psychiatry at Virginia Commonwealth University. “Schizophrenia carries a genetic signature that is overwhelmingly its own. Drug use disorder, by contrast, looks more like a downstream expression of genetic risks that cut across many conditions. That difference has real implications for how we design genetic studies and how we think about diagnostic categories.”

Specificity and Clinical Features

The study similarly found that genetic specificity isn’t fixed. It varies with age at onset, number of recurrences, and treatment setting. Early-onset bipolar disorder had higher genetic specificity than late-onset cases. More recurrent episodes of bipolar disorder were associated with higher specificity. Notably, bipolar patients treated in hospital settings showed significantly higher specificity (63%) than those seen in primary care (31%).

Conversely, PTSD showed increased genetic specificity with later age at onset and was highest among those treated only in primary care (53%) compared to hospitalized patients (41%). Greater recurrence was associated with higher genetic specificity across all nine disorders.

Implications for Research and Clinical Practice

These findings suggest that researchers could tailor genetic study designs by selecting participants to maximize or minimize specificity. Clinicians might use clinical markers – age at onset, recurrence, and treatment history – to inform prognosis and treatment selection.

The contrasting behavior of major depression and bipolar disorder across treatment settings offers further insight. Hospitalized bipolar cases, often due to severe mania, concentrate disorder-specific genetic risk. Hospitalized depression cases, frequently linked to impulsive behaviors and substance use, reflect broader genetic vulnerabilities.

Study Robustness and Limitations

The investigators conducted sensitivity analyses to test the stability of their findings. Results remained consistent even after adjusting for comorbidity. Sex-stratified analyses showed similar genetic specificities between men and women for most disorders, except for alcohol and drug use disorders, where men exhibited higher specificities. The study utilized Swedish national registry data, which, while comprehensive, is not based on research-grade diagnostic interviews. The findings are specific to a Swedish population and may not generalize to other ethnic or geographic groups.

Future Directions

This research opens avenues for further investigation. Future studies could explore whether replication in non-Scandinavian cohorts yields different specificity hierarchies. The findings also highlight the require to consider genetic specificity when designing genetic studies and interpreting diagnostic categories.

“We have been debating whether psychiatric disorders are truly distinct since the 1800s,” Dr. Kendler reflected. “Now we can actually put numbers on it. Some of our diagnostic categories carve nature much more cleanly at the genetic joints than others, and clinicians and researchers alike need to reckon with that.”